| Company Name: |
Centaur Pharmaceuticals Pvt Ltd
|
| Tel: |
+912266499100 |
| Email: |
pawar@centaurchem.com |
| Products Intro: |
Product Name:Loxapine hydrochloride
CAS:54810-23-0
Purity:99% Package:1 kg,5 kg, 10 kg,25kg and 1 MT
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Loxapine hydrochloride
CAS:54810-23-0
Package:100mg/RMB 17500;50mg/RMB 13800;25mg/RMB 10600
|
Loxapine hydrochloride manufacturers
|
| | Loxapine hydrochloride Basic information |
| | Loxapine hydrochloride Chemical Properties |
| | Loxapine hydrochloride Usage And Synthesis |
| Uses | Loxapine hydrochloride is an orally active dopamine inhibitor, 5-HT receptor antagonist and also a dibenzoxazepine anti-psychotic agent[1][4]. | | in vivo | Loxapine (5 mg/kg; i.p.; daily for 4 or 10 weeks) decreases serotonin (S2) but does not elevate dopamine (D2) receptor numbers in the rat brain[3]. | Animal Model: | Adult male Wistar rats (150-175 g)[3] | | Dosage: | 5 mg/kg | | Administration: | Intraperitoneal injection, daily for 4 or 10 weeks | | Result: | Induced a very significant reduction (more than 50%) of serotonin (S2) receptor density after 4 weeks or 10 weeks of daily injection, but did not produce any significant increase in dopamine receptor density. |
| | IC 50 | human 5-HT2; Human D4 Receptor; Human D1 Receptor; Human D2 Receptor | | References | [1] Singh AN, et al. A neurochemical basis for the antipsychotic activity of loxapine: interactions with dopamine D1, D2, D4 and serotonin 5-HT2 receptor subtypes. J Psychiatry Neurosci. 1996 Jan;21(1):29-35. PMID:8580115
[2] Labuzek K, et al. Chlorpromazine and loxapine reduce interleukin-1beta and interleukin-2 release by rat mixed glial and microglial cell cultures. Eur Neuropsychopharmacol. 2005 Jan;15(1):23-30. DOI:10.1016/j.euroneuro.2004.04.002
[3] Lee T, et al. Loxapine and clozapine decrease serotonin (S2) but do not elevate dopamine (D2) receptor numbers in the rat brain. Psychiatry Res. 1984 Aug;12(4):277-85. DOI:10.1016/0165-1781(84)90044-1
[4] Keating GM. Loxapine inhalation powder: a review of its use in the acute treatment of agitation in patients with bipolar disorder or schizophrenia. CNS Drugs. 2013 Jun;27(6):479-89. DOI:10.1007/s40263-013-0075-9 |
| | Loxapine hydrochloride Preparation Products And Raw materials |
|